Literature DB >> 2911838

Beneficial effect of nimodipine on metabolic and functional disturbances in rabbit hippocampus following complete cerebral ischemia.

J W Lazarewicz1, R Pluta, E Salinska, M Puka.   

Abstract

We investigated the effects of intravenous application of nimodipine on the neurophysiologic, biochemical, and morphologic consequences of 15 minutes of global cerebral ischemia in seven rabbits. In vivo dialysis of the hippocampus was used to determine changes in extracellular concentrations of extracellular calcium and amino acids and blood-brain barrier permeability. Ischemia without treatment produced a rapid disappearance of electroencephalographic activity, a decrease in the concentration of extracellular calcium, the release of neuroactive amino acids, and leakage of methionine to the tissue fluid, plus a significant increase of the blood-brain barrier permeability to fluorescein. Except for permeability and electroencephalographic activity, these parameters normalized during 45 minutes of recirculation; permeability and activity failed to normalize completely during 3 hours of recirculation. After 3 hours of recirculation, morphologic changes in the CA1 hippocampal area were observed. Treatment with nimodipine significantly enhanced electroencephalographic activity recovery and normalization during recirculation, reduced the decrease in extracellular calcium concentration, and prevented the increased permeability of the blood-brain barrier. Nimodipine protected the CA1 area from early morphologic changes and reduced leakage of methionine from brain cells. The beneficial cytoprotective effect of nimodipine, probably related to normalization of calcium homeostasis and blood-brain barrier permeability after ischemia, may reflect both vascular and cellular sites of action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2911838     DOI: 10.1161/01.str.20.1.70

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  8 in total

1.  Insulin protects cognitive function in experimental stroke.

Authors:  A J Strong; J E Fairfield; E Monteiro; M Kirby; A R Hogg; M Snape; L Ross-Field
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

2.  Regulation of phosphatidylethanolamine degradation by enzyme(s) of subcellular fractions from cerebral cortex.

Authors:  J Strosznajder
Journal:  Neurochem Res       Date:  1997-10       Impact factor: 3.996

3.  Synergistic internal carotid vasodilator effects of human alpha-calcitonin gene-related peptide and nimodipine in conscious rats.

Authors:  S M Gardiner; A M Compton; T Bennett; P A Kemp; U Ney
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

4.  Comparison of the calcium entry blockers nimodipine and flunarizine on human cerebral and temporal arteries: role in cerebrovascular disorders.

Authors:  I Jansen; P Tfelt-Hansen; L Edvinsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Reassessment of a new model of complete cerebral ischemia in rats. Method of induction of clinical death, pathophysiology and cerebrovascular pathology.

Authors:  R Pluta; A S Lossinsky; M J Mossakowski; L Faso; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

6.  Nimodipine does not affect the flow-metabolism couple in permanent cerebral ischemia.

Authors:  Shintaro Gomi; Mark G Burnett; Andrea Karp; Joel H Greenberg
Journal:  Exp Brain Res       Date:  2004-01-30       Impact factor: 1.972

7.  A Novel Drug Delivery Carrier Comprised of Nimodipine Drug Solution and a Nanoemulsion: Preparation, Characterization, in vitro, and in vivo Studies.

Authors:  Saixu Huang; Zhiyong Huang; Zhiqin Fu; Yamin Shi; Qi Dai; Shuyan Tang; Yongwei Gu; Youfa Xu; Jianming Chen; Xin Wu; Fuzheng Ren
Journal:  Int J Nanomedicine       Date:  2020-02-18

8.  Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study.

Authors:  Xu Song; Yu Jiang; Chunjuan Ren; Xun Sun; Qiang Zhang; Tao Gong; Zhirong Zhang
Journal:  Int J Nanomedicine       Date:  2012-07-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.